J Korean Diabetes.  2019 Sep;20(3):142-148. 10.4093/jkd.2019.20.3.142.

Oral Hypoglycemic Agents for Patients with Type 2 Diabetes Mellitus

• Ko SH

• KMID: 2458963
• DOI: http://doi.org/10.4093/jkd.2019.20.3.142

Abstract

For patients with newly diagnosed type 2 diabetes mellitus (T2DM), lifestyle modifications including medical nutrition therapy, weight control, physical activity, smoking cessation, and avoidance of alcohol abuse should be initiated. Metformin must be considered as the first-line oral glucose-lowering therapy, but other drugs such as dipeptidyl peptidase 4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT-2) inhibitors, thiazolidinediones, glucagon-like peptide 1 receptor agonists, sulfonylureas, glinides, α-glucosidase inhibitors, and insulin can be considered based on patient circumstances. If the initial HbA1c level of a patient is ≥ 7.5% or the HbA1c target is not achieved within three months of initiating monotherapy, dual combination therapy can be considered. If the HbA1c target is not achieved within 3 months of initiating dual therapy, a third agent with a complementary mechanism of action can be added for triple combination therapy. In addition, evidence from large clinical studies assessing cardiovascular outcomes following the use of SGLT-2 inhibitors in T2DM patients with cardiovascular risk factors have been incorporated into the updated recommendations.

Keyword

Diabetes mellitus; Type 2; Hypoglycemic agents; Practice guideline

MeSH Terms

Alcoholism
Diabetes Mellitus
Diabetes Mellitus, Type 2*
Dipeptidyl Peptidase 4
Glucagon-Like Peptide 1
Humans
Hypoglycemic Agents*
Insulin
Life Style
Metformin
Motor Activity
Nutrition Therapy
Risk Factors
Smoking Cessation
Thiazolidinediones
Dipeptidyl Peptidase 4
Glucagon-Like Peptide 1
Hypoglycemic Agents
Insulin
Metformin
Thiazolidinediones